Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 3/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777983 | 1.00 | POLB (0.48) | POLBL3MBTL1FFAR1PPARGOPRD1 | |
| SCHEMBL4066863 | 1.00 | POLB (0.48) | POLBL3MBTL1FFAR1PPARGOPRD1 | |
| SCHEMBL1778076 | 0.94 | POLB (0.42) | POLBL3MBTL1FFAR1PPARG | |
| SCHEMBL1257532 | 0.94 | POLB (0.42) | POLBL3MBTL1FFAR1PPARG | |
| SCHEMBL11996972 | 0.87 | FFAR1 (0.34) | POLBL3MBTL1FFAR1OPRD1 | |
| SCHEMBL1122394 | 0.84 | POLB (0.46) | POLBL3MBTL1FFAR1ACEREN | |
| SCHEMBL17327373 | 0.84 | POLB (0.46) | POLBL3MBTL1FFAR1PPARGOPRD1 | |
| SCHEMBL28245274 | 0.84 | POLB (0.46) | POLBL3MBTL1FFAR1ACEREN | |
| SCHEMBL19083954 | 0.84 | POLB (0.46) | POLBL3MBTL1FFAR1PPARGOPRD1 | |
| SCHEMBL28245271 | 0.84 | POLB (0.46) | POLBL3MBTL1FFAR1ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | POLB 4624/4885L3MBTL1 4729/4885FFAR1 252/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | POLB 4779/4885L3MBTL1 4569/4885FFAR1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.